Immunotherapy of Melanoma
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 1727
Special Issue Editor
Special Issue Information
Dear Colleagues,
Over the past decade the use of anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab and pembrolizumab) antibodies has revolutionized the treatment of cancer. This treatment approach is especially effective in highly immunogenic tumors such as melanoma and demonstrates a highly potent addition to the established treatment options consisting of BRAF and MEK inhibitors.
Despite this significant progress a subset of melanoma patients does not respond to anti-CTLA-4 or anti-PD1 therapy. To a large degree, this is due to the strong immunosuppressive effect the tumor microenvironment has on cytotoxic T cells and natural killer cells, which is mostly mediated by regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). In addition to this obstacle the effect of immune checkpoint therapies in melanoma can be further limited by the occurrence of adverse side effects or primary and aquired resistance mechanisms of the tumor. Therefore, intense efforts are being undertaken to discover new immunotherapy targets, optimize treatment combinations and schedules and validate these findings in clinical trials to improve therapy outcomes.
This Special Issue aims to collect manuscripts related to the identification of novel targets for the immunotherapy of melanoma and ways to remodel the immune composition of the tumor microenvironment to maximize treatment efficacy.
We are inviting the submission of high-quality research papers covering different aspects of this topic. These include (but are not limited to): identification of novel immune checkpoints and design of novel immunotherapeutics, identification of superior drug delivery mechanisms, obstacles and resistance mechanisms to succesful immunotherapy and analysis of clinical treatment approaches.
We are looking forward to receiving your contributions.
Best regards,
Dr. Christopher Groth
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- anti-PD-1
- anti-CTLA-4
- immunosuppression
- immunotherapy
- Tregs
- MDSC
